95-109 mmHg, 24-h mean DBP Ն85 mmHg). Patients had no hepatic or renal impairment, congestive heart failure, or uncontrolled type 2 diabetes (HbA 1C Ն10%). Blood pressure was assessed using 24-h ambulatory blood pressure monitoring, and times of sleep and waking were recorded by patient diary. We calculated blood pressure for the following periods: sleeping mean, awake mean, night-time low (NTL), early morning mean (EMM) and EMBPS (EMM -NTL).
Home measurement and ambulatory 24-hour monitoring of blood pressure (BP) have many advantages over conventional office BP measurement and are increasingly used in clinical practice. However, their effect on the treatment of hypertension requires additional study. We assessed the hypothesis that the adjustment of antihypertensive treatment based on home BP instead of ambulatory BP would lead to equivalent BP control. After a 4-week wash-out period with placebo, a total of 110 patients whose daytime diastolic ambulatory BP averaged 85 mmHg or higher were randomized to either ambulatory BP or home BP groups. Antihypertensive treatment was then adjusted in a stepwise fashion at 6-week intervals according to the mean daytime ambulatory diastolic BP or the mean home diastolic BP during the preceding week, depending on the patient's randomization group. Both ambulatory BP monitoring and home BP measurement were performed on all patients during the study. If the diastolic BP guiding treatment was above 80 mmHg, a physician blinded to the randomization intensified hypertensive treatment; if equal to or below 80 mmHg the treatment was left unchanged. A total of 98 patients completed the study; 52 in the home BP group (age 54Ϯ1.4 y, 37% men) and 46 in the ambulatory BP group (age 54Ϯ1.0 y, 50% men). After a 24-week follow-up period BP was significantly reduced within both groups (pϽ0.01). The between-group differences in systolic and diastolic BP changes were statistically nonsignificant (pϾ0.05). An equal share of patients had progressed to multiple-drug treatment in the home and ambulatory BP groups (65.4% vs. 67.4%, pϭ0.83). We conclude that the adjustment of antihypertensive treatment based on home BP measurement instead of 24-hour ambulatory BP monitoring led to equally intensive drug treatment with preservation of BP control. 
24-h SBP
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Home BP group
Ambulatory BP group Ϫ19.7 Ϯ 1.7 Ϫ12.6 Ϯ 1.1 Ϫ18.6 Ϯ 1.4 Ϫ12.9 Ϯ 0.8 Ϫ17. Home-blood pressure monitoring have been increasingly encouraged by the JNC and the ESH guidelines. Primary prevention is necessary for the management of hypertension in order to facilitate optimal control of blood pressure during the 24 hours of every day. However, prior to marketing, blood pressure measuring devices should be independently validated for safety and accuracy by using standard guidelines.
The clinical evaluation of a new device for self-blood pressure (BP) measurement, the Braun Vital Scan Plus 1650 wrist BP monitor, according to the International Protocol (IP) of the ESH (2002).
Measurements of systolic and diastolic BP in 33 subjects were obtained using the mercury sphygmomanometer (Baumanometer) and the Braun BP VitalScan Plus 1650 device. A heterogeneous group of normotensive and hypertensive patients, still not under treatment, was recruited to assure a wide range of blood pressure, ages, arm and wrist circumferences. Nine sequential same-arm measurements between the test device and the standard mercury sphygmomanometer were carried according to the IP of the ESH in three steps (Phase 1, Phase 2.1 and Phase 2.2).
The device passed Phase 1 and Phase 2.1 as 74 systolic and 77 diastolic readings fell within 5 mmHg exceeding the 65 required for being approved. It also passed the Phase 2.2 as 25 subjects for systolic and 28 for diastolic had at least 2/3 of their comparisons falling within 5 mmHg, exceeding the 22 required and only 2 of the 33 subjects had their three comparisons over 5 mmHg apart. The IP admit that at most 3 subjects may be under that limit. The difference-against-mean plots showed that the device HgS disagreement was -2.57 Ϯ 4.36 for systolic blood pressure (Braun lower) and ϩ0.83 Ϯ 4.97 for diastolic blood pressure (Braun higher) respectively.
Conclusions: The IP tested "subject measurements" and "subject accuracy" of the new device. The equipment passed the different phases satisfactorily. Therefore, it can be used at home for self blood pressure measurements as an adjunct to the physician's effort to control blood pressure in their hypertensive patients.
Key Words: Blood Pressure Measurement, Hypertension
P-92 MP-17 HOME BLOOD PRESSURE MONITORING IMPROVES MEDICATION ADHERENCE
Gbenga Ogedegbe, William Gerin, William Chaplin, Thomas Pickering. Medicine, Columbia University, New York, NY. Home blood pressure monitoring (HBPM) improves blood pressure (BP) control in hypertensive patients. A putative mechanism through which HBPM exerts its effect on BP is via increased medication adherence (ADH). There is no data to support this assumption. In this study, we compared the effects of HBPM versus usual care (UC) on self-reported ADH to prescribed antihypertensive medications. 220 patients were randomly assigned to HBPM and 92 to UC for a period of 12 weeks. Patients in the HBPM group used the life-link monitoring system to assess their HBP, while those in UC received standard care. ADH was assessed at baseline (Visit1) and 12 weeks (Visit2) using the well validated Moritsky questionnaire. Patients were categorized as nonadherent if they responded No to any of the items. Because ADH changes over time in any one individual, we assessed the change in ADH status for each patient from Visit 1 to Visit 2, and then used McNemar's test of dependent proportions to test if the change from non-adherent to adherent was different from the change from adherent to non-adherent for the whole group, the HBPM group and the UC group. 52% were black, 16% were whites and 31% were Hispanics, mean age was 50ϩ 9 yrs, and 81% were female. MeanBP was 146/88 mm hg ϩ 15/9; ADH rate at Visit1 was 57% with a marginally significant difference between UC vs. HBPM 40A AJH-May 2005-VOL. 18, NO. 5, PART 
